Medigus: Revoltz Opens for Pre-Orders of its Revolutionary Micro Mobility EV
04. Januar 2024 07:45 ET
|
Medigus Ltd
Secure your pre-order of the PORTO EV at: https://revoltzev.com/porto/ Tel Aviv, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in...
Odyssey Health, Inc. Provides a Year End Update on Company and Corporate Outlook for 2023
19. Dezember 2022 08:30 ET
|
Odyssey Health, Inc
Las Vegas, Nevada, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing life-enhancing medical products, today...
Odyssey Health, Inc. Schedules Annual Meeting of Stockholders
15. November 2022 08:00 ET
|
Odyssey Health, Inc
Las Vegas, Nevada, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the "Company" or "Odyssey"), a medical technology company focused on...
Odyssey Health Inc. Strengthens Commitment to Odyssey NeuroPharma Through Expansion of Executive Team
03. November 2022 08:30 ET
|
Odyssey Health, Inc
Las Vegas, Nevada, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the "Company" or "Odyssey"), a medical technology company focused on...
Odyssey Health Inc. Files Full US Patent Application on Novel Breath-Propelled Intranasal Brain-Drug Delivery Device
01. November 2022 08:30 ET
|
Odyssey Health, Inc
Las Vegas, Nevada, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the "Company" or "Odyssey"), announces that it has filed for United...
Odyssey Health, Inc. Forms Pharmaceutical Subsidiary Focused on Treating Neurological Diseases
11. Oktober 2022 08:30 ET
|
Odyssey Health, Inc
Las Vegas, Nevada, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical...
Odyssey Health, Inc. Provides Recap on Concussion Drug Development
06. Oktober 2022 08:30 ET
|
Odyssey Health, Inc
Las Vegas, Nevada, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical...
Odyssey Health, Inc. Announces Successful Completion of Phase I Clinical Trial for Concussion Drug
28. September 2022 08:30 ET
|
Odyssey Health, Inc
Las Vegas, Nevada, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical...
Odyssey Health Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial, Cohort II
13. September 2022 08:00 ET
|
Odyssey Health, Inc
Las Vegas, NV, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products,...
Odyssey Health Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial
18. August 2022 08:00 ET
|
Odyssey Health, Inc
Las Vegas, NV, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products,...